PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1620415
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1620415
Alpha-1 Antitrypsin Deficiency Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
The Global Alpha-1 Antitrypsin Deficiency Disease Treatment Market was valued at USD 2.6 billion in 2023 and is expected to grow at a CAGR of 10.1% between 2024 and 2032. This growth is fueled by the rising prevalence of AATD-related respiratory and liver conditions, increased awareness, enhanced screening programs, and advancements in diagnostic and therapeutic options. A significant driver of the market expansion is the increasing incidence of chronic obstructive pulmonary disease (COPD), liver cirrhosis, and other complications associated with AATD. As the number of individuals affected by these conditions grows, so does the demand for effective treatment options. The market is also benefiting from greater awareness efforts and the development of cutting-edge treatments that improve patient outcomes.
In terms of treatment types, the market is segmented into medications, therapies, and surgical interventions. The medication segment, which includes alpha-1 proteinase inhibitors, bronchodilators, and corticosteroids, dominated the market in 2023, accounting for USD 1.9 billion. Medications play a crucial role in managing symptoms and preventing the progression of lung diseases like emphysema and COPD in patients with AATD. The market is further categorized by route of administration, with the parenteral route holding a significant share of 58.1% in 2023. Parenteral administration is important for delivering medications directly into the bloodstream, ensuring rapid absorption and effectiveness-essential for patients needing immediate therapeutic relief.
Geographically, North America is expected to be a key contributor to the market growth, with a projected CAGR of 9.8% through 2032. The region's growth is primarily driven by advancements in therapeutic interventions and a high prevalence of AATD. The aging population in the U.S., which is more prone to AATD-related conditions, further propels the demand for advanced treatments
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $2.6 Billion |
| Forecast Value | $6.2 Billion |
| CAGR | 10.1% |
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of alpha-1 antitrypsin deficiency disease (AATD)
- 3.2.1.2 Advancements in biotechnology
- 3.2.1.3 Approval of novel therapies for AATD
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of treatment
- 3.2.2.2 Adverse effects associated with treatment
- 3.2.1 Growth drivers
- 3.3 Regulatory landscape
- 3.4 Pipeline analysis
- 3.5 Future market trends
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021-2032 ($ Mn)
- 5.1 Key trends
- 5.2 Medication
- 5.2.1 Alpha-1 proteinase inhibitor
- 5.2.2 Bronchodilators
- 5.2.3 Corticosteroids
- 5.2.4 Other medications
- 5.3 Therapy
- 5.3.1 Augmentation therapy
- 5.3.2 Oxygen therapy
- 5.3.3 Other therapies
- 5.4 Surgery
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021-2032 ($ Mn)
- 6.1 Key trends
- 6.2 Parenteral
- 6.3 Intranasal
- 6.4 Oral
Chapter 7 Market Estimates and Forecast, By Age Group, 2021-2032 ($ Mn)
- 7.1 Key trends
- 7.2 Pediatric
- 7.3 Adult
Chapter 8 Market Estimates and Forecast, By End Use, 2021-2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Specialty clinics
- 8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Arrowhead Pharmaceuticals, Inc.
- 10.2 CHIESI Farmaceutici S.p.A.
- 10.3 CSL Behring
- 10.4 Epicrispr Biotechnologies, Inc.
- 10.5 GlaxoSmithKline plc
- 10.6 Grifols S.A.
- 10.7 Intellia Therapeutics, Inc.
- 10.8 Kamada Pharmaceuticals
- 10.9 Mayo Foundation for Medical Education and Research.
- 10.10 National Jewish Health
- 10.11 Shire plc (Takeda Pharmaceutical Company Limited)
- 10.12 The General Hospital Corporation
- 10.13 The Johns Hopkins Hospital
